Masaki Kaibori Selected Research

lenvatinib

3/2024	Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
1/2024	Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
11/2023	α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
11/2023	Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach.
11/2023	Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
10/2023	Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
8/2023	Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
8/2023	Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.
1/2023	Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
1/2023	Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masaki Kaibori Research Topics

Disease

95	Hepatocellular Carcinoma (Hepatoma) 05/2024 - 03/2003
44	Neoplasms (Cancer) 01/2024 - 07/2002
12	Fibrosis (Cirrhosis) 12/2024 - 07/2002
11	Neoplasm Metastasis (Metastasis) 11/2023 - 12/2009
11	Inflammation (Inflammations) 01/2023 - 07/2007
11	Liver Diseases (Liver Disease) 12/2022 - 07/2002
10	Liver Cirrhosis (Hepatic Cirrhosis) 07/2022 - 07/2002
10	Wounds and Injuries (Trauma) 09/2021 - 02/2008
7	Cholangiocarcinoma 01/2023 - 11/2012
6	Hypertension (High Blood Pressure) 01/2023 - 11/2010
6	Acute Liver Failure (Fulminant Hepatic Failure) 12/2022 - 02/2008
6	Infections 08/2021 - 01/2005
6	Liver Failure 11/2011 - 09/2006
5	Liver Neoplasms (Liver Cancer) 05/2024 - 01/2023
5	Reperfusion Injury 12/2022 - 02/2008
5	Carcinoma (Carcinomatosis) 09/2022 - 10/2010
5	Ischemia 10/2021 - 08/2006
4	Fatigue 01/2023 - 07/2015
4	Sepsis (Septicemia) 12/2022 - 07/2011
3	Lymphatic Metastasis 10/2023 - 04/2017
3	Thrombosis (Thrombus) 08/2023 - 11/2010
3	Diarrhea 01/2023 - 07/2015
3	Colorectal Neoplasms (Colorectal Cancer) 03/2022 - 11/2018
3	Pain (Aches) 01/2022 - 07/2015
3	Stomach Neoplasms (Stomach Cancer) 01/2019 - 10/2014
3	Chronic Hepatitis (Chronic Active Hepatitis) 01/2016 - 11/2008
2	Hemorrhage 11/2023 - 08/2022
2	Surgical Wound Infection 06/2023 - 01/2014
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2023 - 06/2020
2	Proteinuria 01/2023 - 01/2023
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2023 - 01/2007
2	Insulin Resistance 05/2022 - 08/2013
2	Hypoxia (Hypoxemia) 01/2022 - 04/2004
2	Diabetes Mellitus 09/2021 - 07/2015
2	Necrosis 01/2020 - 01/2019
2	Obesity 01/2019 - 05/2005
2	Postoperative Pain 07/2015 - 06/2012
2	Ulcerative Colitis 09/2014 - 01/2010

Drug/Important Bio-Agent (IBA)

34	Bevacizumab (Avastin)FDA Link 05/2024 - 01/2022
34	atezolizumabIBA 05/2024 - 01/2022
16	lenvatinibIBA 03/2024 - 12/2021
12	AlbuminsIBA 05/2024 - 11/2008
10	Indocyanine Green (Cardio-Green)FDA LinkGeneric 01/2024 - 03/2003
10	Sorafenib (BAY 43-9006)FDA Link 01/2023 - 11/2010
9	BilirubinIBA 05/2024 - 11/2010
9	Proteins (Proteins, Gene)FDA Link 01/2023 - 08/2006
9	CytokinesIBA 12/2022 - 07/2002
8	alpha-Fetoproteins (alpha-Fetoprotein)IBA 11/2023 - 07/2004
8	Biomarkers (Surrogate Marker)IBA 05/2023 - 09/2014
8	Messenger RNA (mRNA)IBA 01/2022 - 08/2006
7	Fetal Proteins (Fetoprotein)IBA 05/2024 - 10/2022
6	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2019 - 07/2002
5	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2024 - 01/2017
5	Serum AlbuminIBA 10/2023 - 02/2013
5	acarboxyprothrombin (PIVKA)IBA 08/2023 - 07/2004
5	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 11/2010
5	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2020 - 08/2006
4	AcidsIBA 06/2020 - 06/2014
4	Vitamin K FDA Link 10/2010 - 04/2007
3	Anti-Bacterial Agents (Antibiotics)IBA 08/2023 - 01/2014
3	NF-kappa B (NF-kB)IBA 10/2019 - 02/2008
3	EdaravoneIBA 12/2008 - 01/2005
2	Photosensitizing Agents (Photosensitizers)IBA 01/2024 - 09/2022
2	Liposomes (Liposome)IBA 01/2024 - 06/2022
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2023 - 01/2022
2	Tumor Biomarkers (Tumor Markers)IBA 08/2023 - 11/2012
2	Indicators and Reagents (Reagents)IBA 01/2023 - 01/2023
2	C-Reactive ProteinIBA 01/2023 - 10/2022
2	Simendan (Levosimendan)IBA 12/2022 - 01/2019
2	RNA (Ribonucleic Acid)IBA 09/2022 - 01/2022
2	HydrogenIBA 06/2022 - 10/2021
2	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 11/2021 - 05/2021
2	Active Hexose Correlated CompoundIBA 11/2019 - 08/2014
2	ChemokinesIBA 10/2019 - 03/2008
2	Antineoplastic Agents (Antineoplastics)IBA 09/2019 - 01/2017
2	Therapeutic UsesIBA 09/2019 - 01/2010
2	Interleukin-6 (Interleukin 6)IBA 01/2019 - 09/2005
2	InterleukinsIBA 01/2019 - 08/2006
2	OligonucleotidesIBA 01/2018 - 04/2013
2	Fluvastatin FDA Link 09/2014 - 07/2013

Therapy/Procedure

45	Hepatectomy 10/2023 - 07/2002
27	Therapeutics 12/2024 - 07/2002
12	Drug Therapy (Chemotherapy) 06/2022 - 11/2010
7	Liver Transplantation 12/2024 - 05/2005
5	Photochemotherapy (Photodynamic Therapy) 01/2024 - 01/2017
5	Blood Transfusion (Blood Transfusions) 01/2018 - 04/2007
4	Segmental Mastectomy (Lumpectomy) 07/2022 - 11/2012
4	Neoadjuvant Therapy 01/2022 - 12/2009
4	Kampo Medicine (Kampo) 01/2020 - 01/2012
4	Gastrectomy 01/2019 - 10/2014
3	Aftercare (After-Treatment) 06/2022 - 01/2016
3	Sutures (Suture) 01/2022 - 08/2016
3	Adjuvant Chemotherapy 01/2022 - 07/2007
3	Length of Stay 01/2015 - 01/2014
2	Catheters 10/2023 - 06/2014
2	Oral Administration 01/2023 - 09/2014
2	Respiratory Therapy (Therapy, Respiratory) 06/2022 - 10/2021
2	Exercise Therapy (Therapy, Exercise) 05/2022 - 08/2013
2	Transplantation 11/2019 - 11/2006
2	Radiofrequency Ablation 01/2016 - 07/2015